MicroVision MOVIA lidar gains support on NVIDIA DRIVE AGX platform
James O. Hearty, Chief Compliance Officer at DaVita Inc (NYSE:DVA), a prominent player in the Healthcare Providers & Services industry with an excellent overall financial health score according to InvestingPro, sold 2,351 shares of common stock on July 23, 2025. The shares were sold at a price of $150.0, for a total transaction value of $352,650.
Following the transaction, Hearty directly owns 26,038 shares of DaVita Inc. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2025.
In other recent news, DaVita reported its first-quarter earnings for 2025, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $2.00, compared to the forecasted $1.96. The company also reported revenue of $3.22 billion, slightly above the projected $3.20 billion. Additionally, DaVita has upsized its private offering of senior notes due 2033, increasing the aggregate principal amount from $750 million to $1 billion. The proceeds from this offering are primarily intended to repay existing revolving credit facility borrowings and associated accrued interest. In other developments, TD Cowen maintained a Hold rating on DaVita but reduced the stock price target from $165 to $157, following first-quarter results that fell short of adjusted EBIT expectations. DaVita has revised its full-year 2025 volume expectations downward due to flu-related census declines and other factors. Despite these challenges, the company has reiterated its full-year guidance for EBIT, EPS, and free cash flow. Lastly, DaVita expressed support for the extension of the Kidney Care Choices Model by the Center for Medicare and Medicaid Innovation, highlighting its commitment to improving kidney care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.